脓毒症相关性血小板减少症的研究及治疗进展

Advances in research and treatment of sepsis related thrombocytopenia

关键词:  脓毒症  序贯器官衰竭评分  血小板减少症

Key words:  sepsis  SOFA  thrombocytopenia

摘要:

脓毒症是机体对感染的反应失调而导致的危及生命的器官功能障碍，目前脓毒症相关性血小板减少症的机制主要包括血小板生成减少、消耗增加、免疫因素等。准确找寻脓毒症相关性血小板减少症的病因，针对病因，控制感染等是治疗关键。目前临床上多基于循证医学的血小板输注指南推荐证据，严格掌握其输注指征，结合患者病情进行输注血小板。该病患者除输注血小板外，亦可通过输注重组人促血小板生成素（rhTPO）或重组人白介素11（rhIL-11）治疗。本文对脓毒症相关性血小板减少症的机制及治疗进行综述。

Abstract:

Sepsis is a life-threatening organ dysfunction caused by the maladjustment of the body's response to infection. Currently, the mechanism of sepsis-associated thrombocytopenia mainly includes decreased platelet generation, increased consumption and immune factors. Accurately finding the etiology of sepsis-associated thrombocytopenia, aiming at the etiology and controlling infection are the key to treatment. At present, clinical practice is mostly based on the recommendation of platelet transfusion guidelines recommended by evidence-based medicine. It is necessary to strictly grasp the indication of platelet transfusion and conduct platelet transfusion in combination with the patient's condition. In addition to platelet transfusion, patients with the disease can also be treated by infusion of Recombinant human thrombopoietin (rhTPO) or recombinant human interleukin-11 (rhIL-11). This article reviews the mechanism and treatment of sepsis-associated thrombocytopenia.